Jose Ruiz-Iglesias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose Ruiz-Iglesias has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ernest Palomer
Molecular Neuropathology Unit, Physiological and Pathological Processes Program, Centro de Biologia Molecular Severo Ochoa (CBM), CSIC-UAM, Madrid, Spain
2 shared publications - Javier Isoler-Alcaraz
Molecular Neuropathology Unit, Physiological and Pathological Processes Program Centro de Biología Molecular Severo Ochoa, CSIC‐UAM Madrid Spain
2 shared publications - Lucía Cañizares‐Moscato
Molecular Neuropathology Unit, Physiological and Pathological Processes Program Centro de Biología Molecular Severo Ochoa, CSIC‐UAM Madrid Spain
2 shared publications - Adrián de Rus-Moreno
Genome maintenance and instability Unit, Genome dynamics and function Program, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049, Madrid, Spain
1 shared publication - Aida Contreras-Pérez
Genome maintenance and instability Unit, Genome dynamics and function Program, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049, Madrid, Spain
1 shared publication - Alicia Gómez-Moya
Genome maintenance and instability Unit, Genome dynamics and function Program, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (5)
Beyond Bulk: Cell‐Type‐Resolved Epigenomics as the Path Forward in Alzheimer's Disease Research
Alzheimer's disease (AD) is a complex neurodegenerative disorder in which most risk variants are noncoding and are enriched at gene regulatory regions, implicating epigenetic mechanisms as central mediators of disease pathogenesis. For most of the history of AD epigenetics research, bulk tissue analysis has dominated, obscuring the fundamentally distinct epigenomic landscapes of individual brain cell types and masking cell‐type‐specific contributions to disease. Advances in single‐cell and single‐nucleus sequencing, fluorescence‐activated nuclei sorting and multiplexed epigenomic platforms have transformed this landscape, enabling cell‐type‐resolved profiling of chromatin accessibility, DNA methylation, histone modifications and transcription across the major neuronal, glial and neurovascular populations of the human brain. Here, we review these advances, structured around the argument that cell‐type resolution is not a methodological refinement but a conceptual necessity. We describe the distinct epigenomic programs disrupted in neurons, microglia, astrocytes, oligodendrocytes and neurovascular cells in AD, highlighting how each cell type responds to pathology. We discuss the discovery of epigenomic erosion, the progressive loss of cell‐type‐specific epigenomic identity across virtually all brain cell populations as AD advances, as a unifying disease mechanism linking chromatin dysregulation to cognitive decline. Finally, we identify critical gaps in current knowledge, including the near‐complete absence of cell‐type‐resolved histone modification and DNA methylation data for most brain cell types, the underrepresentation of rare populations in standard preparations and the untapped potential of metabolic acylation marks as indicators of the epigenome–metabolism interface in neurodegeneration.
- 9 September 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (5)
Open AccessBeyond Bulk: Cell‐Type‐Resolved Epigenomics as the Path Forward in Alzheimer's Disease Research
Alzheimer's disease (AD) is a complex neurodegenerative disorder in which most risk variants are noncoding and are enriched at gene regulatory regions, implicating epigenetic mechanisms as central mediators of disease pathogenesis. For most of the history of AD epigenetics research, bulk tissue analysis has dominated, obscuring the fundamentally distinct epigenomic landscapes of individual brain cell types and masking cell‐type‐specific contributions to disease. Advances in single‐cell and single‐nucleus sequencing, fluorescence‐activated nuclei sorting and multiplexed epigenomic platforms have transformed this landscape, enabling cell‐type‐resolved profiling of chromatin accessibility, DNA methylation, histone modifications and transcription across the major neuronal, glial and neurovascular populations of the human brain. Here, we review these advances, structured around the argument that cell‐type resolution is not a methodological refinement but a conceptual necessity. We describe the distinct epigenomic programs disrupted in neurons, microglia, astrocytes, oligodendrocytes and neurovascular cells in AD, highlighting how each cell type responds to pathology. We discuss the discovery of epigenomic erosion, the progressive loss of cell‐type‐specific epigenomic identity across virtually all brain cell populations as AD advances, as a unifying disease mechanism linking chromatin dysregulation to cognitive decline. Finally, we identify critical gaps in current knowledge, including the near‐complete absence of cell‐type‐resolved histone modification and DNA methylation data for most brain cell types, the underrepresentation of rare populations in standard preparations and the untapped potential of metabolic acylation marks as indicators of the epigenome–metabolism interface in neurodegeneration.
- Open Access
EpiFlow: multidimensional single-cell epigenetic profiling by spectral flow cytometry
The epigenetic landscape of individual cells determines their identity and function, yet current methods for profiling chromatin modifications at single-cell resolution remain low-throughput, costly, or limited in parametric depth. Here we present EpiFlow, a spectral flow cytometry-based platform that enables the simultaneous quantification of 16 epigenetic markers, including histone post-translational modifications, DNA methylation, and hydroxymethylation, at the single-cell level. We demonstrate that EpiFlow is robust across species from yeast to mammals and resolves biologically meaningful epigenetic transitions during the cell cycle, stem cell differentiation, germinal centre B cell maturation, diabetic liver remodelling, and seizure-induced chromatin reprogramming. High-dimensional integration of EpiFlow data enables cell-type classification based solely on epigenetic profiles in liver, brain, blood, and cancer. Furthermore, EpiFlow detects on-target and off-target/indirect effects of epigenetic drugs in a high-throughput-compatible format. Collectively, these results establish EpiFlow as a broadly applicable platform for single-cell epigenetic analysis in basic, pharmaceutical, and translational research.
Open AccessEpiFlow: multidimensional single-cell epigenetic profiling by spectral flow cytometry
The epigenetic landscape of individual cells determines their identity and function, yet current methods for profiling chromatin modifications at single-cell resolution remain low-throughput, costly, or limited in parametric depth. Here we present EpiFlow, a spectral flow cytometry-based platform that enables the simultaneous quantification of 16 epigenetic markers, including histone post-translational modifications, DNA methylation, and hydroxymethylation, at the single-cell level. We demonstrate that EpiFlow is robust across species from yeast to mammals and resolves biologically meaningful epigenetic transitions during the cell cycle, stem cell differentiation, germinal centre B cell maturation, diabetic liver remodelling, and seizure-induced chromatin reprogramming. High-dimensional integration of EpiFlow data enables cell-type classification based solely on epigenetic profiles in liver, brain, blood, and cancer. Furthermore, EpiFlow detects on-target and off-target/indirect effects of epigenetic drugs in a high-throughput-compatible format. Collectively, these results establish EpiFlow as a broadly applicable platform for single-cell epigenetic analysis in basic, pharmaceutical, and translational research.